Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma

International Journal of Radiation Oncology Biology Physics

Volumn 85, Issue 5, 2013, Pages 1275-1281

  Heath, C Hope ^a   Deep, Nicholas L ^a   Nabell, Lisle ^a   Carroll, William R ^a   Desmond, Renee ^a   Clemons, Lisa ^a   Spencer, Sharon ^a   Magnuson, J Scott ^a   Rosenthal, Eben L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT RADIATION THERAPIES; CANCER RECURRENCE; CUTANEOUS SQUAMOUS CELL CARCINOMATA; DISEASE FREE SURVIVAL; HEAD-AND-NECK SQUAMOUS CELL CARCINOMA; KAPLAN-MEIER METHOD; METHODS AND MATERIALS; RECURRENCE RATES;

CELLS; CYTOLOGY; TOXICITY;

RADIOTHERAPY;

CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN KINASE B;

ADULT; ADVANCED CANCER; AFRICAN AMERICAN; AGED; ARTICLE; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CAUCASIAN; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; EDEMA; ESOPHAGITIS; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; OPEN STUDY; PAROTID GLAND; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN CARCINOMA; VOMITING; XEROSTOMIA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIODERMATITIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; STOMATITIS;

EID: 84875277576     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.09.030     Document Type: Article

References (23)

1. M. Alam, and D. Ratner Cutaneous squamous-cell carcinoma N Engl J Med 344 2001 975 983
2. N.R. Dean, L. Sweeny, and J.S. Magnuson Outcomes of recurrent head and neck cutaneous squamous cell carcinoma J Skin Cancer 2011 2011 972497
3. M. Baumann, and M. Krause Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 2004 257 266
4. L. Sweeny, N.R. Dean, and J.S. Magnuson EGFR expression in advanced head and neck cutaneous squamous cell carcinoma Head Neck 34 2012 681 686
5. M. Baltaci, P. Fritsch, and F. Weber Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma Br J Dermatol 153 2005 234 236
6. E.E. Cohen, D.J. Haraf, and R. Kunnavakkam Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 28 2010 3336 3343
7. K. Saarilahti, P. Bono, and M. Kajanti Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer J Otolaryngol Head Neck Surg 39 2010 269 276
8. T. Lardaro, S.M. Shea, and W. Sharfman Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging Manual Ann Surg Oncol 17 2010 1979 1980
9. M. Mirshams, M. Razzaghi, and P. Noormohammadpour Incidence of incomplete excision in surgically treated cutaneous squamous cell carcinoma and identification of the related risk factors Acta Med Iranica 49 2011 806 809
10. D.M. Peereboom, D.R. Shepard, and M.S. Ahluwalia Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme J Neurooncol 98 2010 93 99
11. J.D. Hainsworth, D.R. Spigel, and H.A. Burris 3rd Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck Cancer 115 2009 2138 2146
12. C.M. Lewis, B.S. Glisson, and L. Feng A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck Clin Cancer Res 18 2012 1435 1446
13. T. Li, and R. Perez-Soler Skin toxicities associated with epidermal growth factor receptor inhibitors Target Oncol 4 2009 107 119
14. E. Roe, M.P. Garcia Muret, and E. Marcuello Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients J Am Acad Dermatol 55 2006 429 437
15. D. Soulieres, N.N. Senzer, and E.E. Vokes Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77 85
16. D.J. Adelstein, Y. Li, and G.L. Adams An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer J Clin Oncol 21 2003 92 98
17. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 2006 567 578
18. K.K. Fu, T.F. Pajak, and A. Trotti A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 Int J Radiat Oncol Biol Phys 48 2000 7 16
19. M.J. Veness Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma Australas Radiol 49 2005 365 376
20. D. Sano, M.K. Gule, and D.I. Rosenthal Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo Head Neck 2012 Feb 24. 2012. [Epub ahead of print]
21. S.J. Kalapurakal, J. Malone, and K.T. Robbins Cetuximab in refractory skin cancer treatment J Cancer 3 2012 257 261
22. J. Kao, E.M. Genden, and C.T. Chen Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer Cancer 117 2011 3173
23. C. Chen, M. Kane, and J. Song Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer J Clin Oncol 25 2007 4880